Macquarie Group
ASND icon

Macquarie Group’s Ascendis Pharma A/S ASND Stock Holding History

Macquarie Group’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-309,539
Closed -$61.5M – 904
2025
Q3 		$61.5M Buy
309,539
+192,804
+165% +$36M 0.07% 366
2025
Q2 		$20.1M Buy
+116,735
New +$19M 0.02% 665

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Macquarie Group's ASND Position: Q4 2025 in Review

Macquarie Group sold out of Ascendis Pharma A/S (ASND) in Q4 2025, closing a stake of 309,539 shares — an estimated $61.5M sold.

Macquarie Group first reported a position in ASND in Q2 2025 and held it in 2 quarters. The position peaked at $61.5M in Q3 2025. 302 funds tracked by Wall St. Rank hold ASND as of Q4 2025.

  • Macquarie Group reported no remaining Ascendis Pharma A/S position as of Q4 2025 after selling out during the quarter.
  • Macquarie Group sold 309,539 Ascendis Pharma A/S shares in Q4 2025, an estimated $61.5M.
  • Macquarie Group first reported a position in Ascendis Pharma A/S in Q2 2025 and held it in 2 quarters.
  • Macquarie Group's Ascendis Pharma A/S position peaked at $61.5M in Q3 2025.
  • 302 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2025.

Based on Macquarie Group's 13F filing for Q4 2025, filed 13 Feb 2026.